Stock 688073 BIDE PHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bide Pharmatech Co., Ltd.

Equities

688073

CNE100005NV3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
36.34 CNY -4.84% Intraday chart for Bide Pharmatech Co., Ltd. +3.50% -34.52%
Apr. 25 Bide Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Tranche Update on Bide Pharmatech Co., Ltd.'s Equity Buyback Plan announced on December 9, 2023. CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 5,333 5,044 3,303 - -
Enterprise Value (EV) 1 5,333 5,044 3,303 3,303 3,303
P/E ratio 29.7 x 45.9 x 13.3 x 11.3 x 15.7 x
Yield - 1.62% - - -
Capitalization / Revenue 6.4 x 4.62 x 2.56 x 1.76 x 1.74 x
EV / Revenue 6.4 x 4.62 x 2.56 x 1.76 x 1.74 x
EV / EBITDA 28.6 x 33.6 x 15 x 10.9 x 14 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 2.57 x 2.41 x 1.54 x 1.28 x 1.42 x
Nbr of stocks (in thousands) 90,883 90,883 90,883 - -
Reference price 2 58.68 55.50 36.34 36.34 36.34
Announcement Date 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 833.8 1,092 1,288 1,881 1,899
EBITDA 1 - 186.2 150.3 220.3 302.7 236
EBIT 1 - 171.7 126.6 258.2 344.8 246
Operating Margin - 20.6% 11.6% 20.05% 18.32% 12.96%
Earnings before Tax (EBT) 1 - 171.8 126 292.3 344.8 246
Net income 1 97.57 146 109.6 248.7 293.4 210.1
Net margin - 17.51% 10.04% 19.31% 15.6% 11.07%
EPS 2 1.457 1.979 1.210 2.740 3.228 2.310
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - 0.9000 - - -
Announcement Date 9/14/22 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 14.2% 5.28% 6.2% 11.2% 9.04%
ROA (Net income/ Total Assets) - 8.94% - 5.2% 8.83% 7.4%
Assets 1 - 1,633 - 4,783 3,322 2,840
Book Value Per Share 2 - 22.80 23.00 23.60 28.30 25.60
Cash Flow per Share 2 - 0.3300 -0.6300 0.6500 1.110 -
Capex 1 - 38.4 60.2 57.7 33.7 36
Capex / Sales - 4.61% 5.51% 4.48% 1.79% 1.9%
Announcement Date 9/14/22 1/13/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bide Pharmatech Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
36.34 CNY
Average target price
41 CNY
Spread / Average Target
+12.82%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIDE PHARMATECH CO., LTD. Stock Bide Pharmatech Co., Ltd.
-34.52% 457M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 688073 Stock
  4. Financials Bide Pharmatech Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW